# Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Study · id `cardio:ct-nct03635996` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03635996](<https://clinicaltrials.gov/study/NCT03635996>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03635996

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 169 participants.

## Technical summary

Registry record NCT03635996. Allocation not applicable; no masking; primary purpose treatment. Start 2018-12-10 (actual); primary completion 2020-11-13 (actual). Results posted on 2023-04-24.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 169 participants (enrolled count; ClinicalTrials.gov record NCT03635996, source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)
- Started: 2018-12-10 (actual) (ClinicalTrials.gov record NCT03635996, source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)
- Primary completion: 2020-11-13 (actual) (ClinicalTrials.gov record NCT03635996, source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)
- Completion: 2020-11-13 (actual) (ClinicalTrials.gov record NCT03635996, source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)
- Results first posted: 2023-04-24 (ClinicalTrials.gov record NCT03635996, source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT03635996, source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03635996-2024-11-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
- Condition: Paroxysmal Supraventricular Tachycardia
- Intervention (Drug): Etripamil NS 70 mg
- Intervention (Device): Aptar Pharma Nasal Spray Bidose System
- Lead sponsor: Milestone Pharmaceuticals Inc.
- Lead sponsor class: OTHER
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Milestone Pharmaceuticals Inc. (`cardio:org-milestone-pharmaceuticals-inc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study (`cardio:pubmed-37753718`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c92652334f1d0400a6ba4157e9b0814ca6b17fb5fd81deb6cc4ca29b16ecd05e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
